MedTrace Logo

CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients

NCT03732430 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2018-11-29

No results posted yet for this study

Summary

This phase II study is to evaluate the safety and efficacy of CT-based adaptive radiation therapy followed by adjuvant anti-PD-1 antibody immunotherapy in treating patients with different types and stages of thoracic malignancies. (CARTAI)

Conditions

  • Thoracic Malignancies

Interventions

DRUG

IBI308

A humanized anti-PD-1 monoclonal antibody

Sponsors & Collaborators

  • Taizhou Hospital

    lead OTHER

Principal Investigators

  • Fengming (Spring) Kong, MD · Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

  • Haihua Yang, MD · Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

  • Yinnan Meng, MD · Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-14
Primary Completion
2020-12-31
Completion
2022-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03732430 on ClinicalTrials.gov